Theseus Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Iain D. Dukes DPHIL,
- Full Time Employees
- 38
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 245 Main Street Cambridge MA United States of America 02142
- IPO Date
- Oct 7, 2021
- CIK
- 0001745020
- Website
- theseusrx.com
- Similar Companies
- Business
- Theseus Pharmaceuticals, Inc. (THRX) operates as a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company advances precision oncology medicines, including its lead candidate ORIC-114, a brain penetrant, irreversible inhibitor of EGFR and HER2 oncogenic mutations targeting glioblastoma, non-small cell lung cancer, and other solid tumors; ORIC-533, an antagonist of the glucocorticoid receptor designed to block cortisol-mediated resistance in patients with multiple myeloma; and ORIC-944, an allosteric antagonist of the androgen receptor for prostate cancer. These programs emphasize oncology indications with high unmet needs, such as genomically defined patient subsets in solid tumors and hematologic malignancies. Founded in 2019 and headquartered in South San Francisco, California, the company conducts operations primarily in the United States. In recent developments, Theseus completed its initial public offering on NASDAQ in 2023, raising net proceeds to support clinical advancement of its pipeline; discontinued ORIC-114 following interim data from the Phase 1/2 trial in 2024 due to limited efficacy; and announced a strategic merger with Concentrix Bio in October 2024, positioning the combined entity to advance next-generation cancer therapies.
Theseus Pharmaceuticals Announces Closing of Tender Offer
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?
Shareholder Alert: Ademi LLP investigates whether Theseus Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Concentra
THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure
Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
New Strong Buy Stocks for July 19th
After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me
Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study
Why Is Theseus Pharmaceuticals (THRX) Stock Down 68% Today?
Why These 2 Biotech Stocks Made Big Moves Late Thursday
Theseus Pharmaceuticals stock plummets after cancer drug development stopped
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST